Kornimate/medical-research-clean huggingface dataset:
physical endometrial manipulation and its effect on icsi

Conditions: Infertility

Summary: unexplained infertility is clinically diagnosed when there are no apparent or clear factors causing infertility on regular infertility assessment tools . failure of implantation is a possible factor causing unexplained infertility . implantation is the main rate limiting step in ivf outcome. implantation is described at cellular and molecular level by adhesion or fixation of good quality embryo to receptive endometrium within a critical period of time which is called the window of implantation .

testing the effect of physical manipulation of the endometrium on the quality of the endometrium prior to icsi cycle and if it increases the success rate

Eligibility criteria:
inclusion criteria: * infertile female age 20-35 years * previous failed one icsi trial * normal basal hormonal profile \[fsh, lh\] 3-10 miu/ml and 1.8-8.5 miu/ml respectively, --normal endometrial cavity * patent tubes * normal husband semen analysis exclusion criteria: * ovarian factor of infertility * tubal factor of infertility * endometrial factor of infertility * male factor of infertility

Keywords: icsi - physical - manipulation - scratching
long-term effects of an early individualised retraining programme on walking ability in patients following hemiplegic stroke

Conditions: Stroke

Summary: this project aims to study the effects early individualised retraining programme on walking ability in patients following hemiplegic stroke.


Eligibility criteria:
inclusion criteria: * patients benefiting from classical rehabilitation following cardiovascular accident (cerebral infarction or spontaneous intracerebral hematoma) according to current recommendations (conference de consensus sur l'orientation des patients atteints d'avc des societes françaises de medecine physique et readaptation (mpr), d'urgence neuro-vasculaire et de geriatrie et gerontologie), hospitalized in the physical medicine and rehabilitation (pmr) units of dijon and besançon chu, and the functional rehabilitation centres of divio (dijon) and bregille (besançon) * age between 18 and 85 years. * etiological examination carried out according to current recommendations (ct scan and/or mri, holter ecg and holter blood pressure, doppler of the supra-aortic trunks, echocardiography). * patients referred to the pmr unit less than one month after the cerebral vascular accident. * clinical status considered stable from a cardiovascular and neurological point of view with a well-balanced medical treatment (anti-hypertensives, anti-coagulants or antiplatelets, oral antidiabetics if necessary) * patients able to understand the instructions and the interest of retraining. * patients who have provided written informed consent for the study. exclusion criteria: * existence of disorders associated with hemiplegic motor impairment: disorders of memory and superior functions (mmse \< 24) and impaired ability to understand (bdae \<3), deep sensitivity disorders, severe unilateral neglect (bells test). * patients referred following meningeal hemorrhage or deep vein thrombosis * recurrent stroke, whatever the severity of the sequelae of the previous stroke. * existence of cerebellar involvement as a major aspect of the clinical picture * myocardial infarction or heart surgery within the preceding 6 months. * severe heart failure (nyha \>3 or left ventricular ejection fraction (lvef) \<40%). * subjects presenting with complete non-stabilized arrhythmia * any metabolic, infectious, inflammatory, respiratory or cardiovascular disease that is not stabilized or constitutes a contra indication to retraining (chronic respiratory insufficiency (obstructive or restrictive), severe valve disease, obstructive heart disease, severe progressive heart rhythm or conduction disorders, intracavitary thrombus. * symptomatic peripheralartery disease (leriche and fontaine stage 3 or 4). * any other debilitating neurological disease (multiple sclerosis, parkinson's disease). * participation in another biomedical research protocol during the retraining period (8 weeks minimum) * patients under guardianship or ward of court.
the invader™ percutaneous transluminal coronary angioplasty (ptca) post market clinical follow-up (pmcf) study

Conditions: Coronary Artery Disease; Coronary Disease; Vascular Diseases

Summary: the aim of the present observational study is to collect clinical data on the non-implantable medical device invader™ ptca in the daily use in an unselected population.


Eligibility criteria:
inclusion criteria: * to be a turkish citizen, * to be \>18 years of age, * lesion must be successfully crossed with a guidewire without complication, * invader™ ptca is used in the primary lesion treated during the procedure, * patient has signed and dated the informed consent. exclusion criteria: * patients who have a known allergic reaction to any of the composition of invader™ ptca balloon dilatation catheter. * device use not consistent with instructions for use (ifu). * patients concurrently participating in another medical device or pharmaceutical clinical trial.
improving negative symptoms of psychosis in real-world environments

Conditions: Schizophrenia

Summary: this study will compare cognitive behavioral social skills training-compensatory cognitive training (cbsst-cct) to a goal-focused supportive contact group to see which intervention better improves symptoms and functioning in people with schizophrenia.


Eligibility criteria:
inclusion criteria: must be a resident of broadway home, san diego, or a service user of the meeting place, areta crowell, or project enable. 1. voluntary informed consent to participate 2. age 18 to 65 3. dsm-iv diagnosis of schizophrenia or schizoaffective disorder based on mini/scid 4. moderate-to-severe negative symptoms on the clinical assessment interview for negative symptoms (cains total score \>19) 5. ≥ 6th grade reading level on the wide range achievement test-4 reading subtest (needed for reading treatment manual) 6. stable on medications; no changes within 3 months prior to enrollment exclusion criteria: 1. prior cbt, sst, or cct in the past 5 years 2. severe positive symptoms on the positive and negative syndrome scale (panss delusions, disorganization, hallucinations, or suspiciousness \>5) 3. severe depression on the calgary depression scale for schizophrenia (cdss \>8) 4. ocular damage/disease/surgery/medications that affect pupil dilation 5. dsm-iv alcohol or substance dependence diagnosis in past 6 months based on the mini or scid 6. level of care required interferes with outpatient therapy (e.g., hospitalized; severe medical illness) .

Keywords: negative symptoms cognition functioning defeatist attitudes psychosocial treatment
a study of ketamine infusions to treat clinically-depressed icu patients

Conditions: Depression

Summary: the purpose of this research is to study the effects of intravenous ketamine infusions for the treatment of patients with depressive symptoms in intensive care unit (icu).


Eligibility criteria:
inclusion criteria: * has been in the mayo clinic florida icu for the past 1 week. * phq-9 score of 10 or higher. * one of the following diagnoses: acute myocardial infarction; acute renal failure; chronic obstructive pulmonary disease (copd); congestive heart failure; end-stage liver disease; patients requiring intra-aortic balloon pump (iabp) therapy or continuous renal replacement therapy (crrt); post-bone marrow transplant; acute hypoxemic respiratory failure; acute or chronic hypoxemic respiratory failure; pre- or post- lung, liver or heart transplant or surgical overflows (such as abdominal aortic aneurysm, thoracotomy or tracheostomy). exclusion criteria: * poor vital sign stability hypoxia: o2 \ 180. * heart rate: \ 120, or respiratory rate: \ 30. * altered mental status. * patient is unwilling to participate or provide informed consent. * any allergy to ketamine or diphenhydramine. * patient is female of child-bearing age and unwilling to provide urine or blood for hcg analysis. * pregnant or breastfeeding. * presence of intracranial mass or vascular lesion. * presence of a history of psychosis or hallucinations (as assessed by electronic chart review). * weight greater than 115 kg or less than 45kg. * history of increased intracranial pressure/hypertensive hydrocephalus or increased intraocular pressure. * patient is acutely psychotic. * provider feels that patient currently or likely will require chemical and/or physical restraints. * history of prolonged qt-interval. * current treatment includes any medication known to affect the n-methyl-d-aspartate receptor system (e.g., lamotrigine, acamprosate, memantine, riluzole, or lithium). * patient in withdrawal from substance abuse or who have used hallucinogens (including cannabis) in the last month for any indication, as determined by the clinical interview and urine drug screening.
determining the optimal examined lymph node for accurate staging and long-term survival in rectal cancer

Conditions: Rectal Cancer

Summary: a multi-institutional registry of collected data on patients with rectal cancer who underwent surgical resection between january 2009 and december 2018 at the departments of colorectal surgery of five medical institutions in china

a multi-institutional registry of collected data on patients with rectal cancer who underwent surgical resection between january 2009 and december 2018 at the departments of colorectal surgery of five medical institutions in china (national cancer center/national clinical research center for cancer/cancer hospital, chinese academy of medical sciences and peking union medical college; changhai hospital, naval medical university; the second affiliated hospital of harbin medical university; the affiliated tumor hospital of harbin medical university; the affiliated tumor hospital of guangxi medical university)

Eligibility criteria:
inclusion criteria: * rectal cancer patients in stage i-iii who underwent surgical resection for first primary rectal cancer with at least one lymph node were eligible exclusion criteria: * patients with missing values on lymph node count and clinical features were excluded
the effect of qva149 on health related quality of life in patients with chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: this study will assess the efficacy and safety of qva149 compared to tiotropium plus formoterol in patients with moderate to severe copd.


Eligibility criteria:
inclusion criteria: * male or female adults aged ≥ 40 yrs * patients with moderate to severe chronic obstructive pulmonary disease (gold 2010 guidelines) * smoking history of at least 10 pack years * post-bronchodilator fev1 \< 80% and ≥30% of the predicted normal value and post-bronchodilator fev1/fvc (forced vital capacity) \<70% exclusion criteria: * pregnant women or nursing mothers or women of child-bearing potential not using adequate contraception * patients with a history of long qt syndrome * patients with type i or uncontrolled type ii diabetes * patients who have had a copd exacerbation or respiratory tract infection within 6 weeks prior to screening * patients with any history of asthma * patients with pulmonary lobectomy, lung volume reduction surgery, or lung transplantation * patients with concomitant pulmonary disease * patients requiring long term oxygen therapy (\>15 h a day) other protocol-defined inclusion/exclusion criteria may apply.

Keywords: qva149 health related quality of life formoterol tiotropium copd
aprepitant and fosaprepitant time-on-target pet (positron emission tomography) study (0869-183)

Conditions: Chemotherapy-Induced Nausea and Vomiting (CINV)

Summary: this study will evaluate if the mean value of brain neurokinin 1 (nk1)-receptor occupancy of participants treated with aprepitant is similar to that of participants treated with fosaprepitant at certain timepoints.

the third arm of the study (aprepitant 250 mg) will only be conducted if the real-time assessment of the nk1-receptor occupancy data between fosaprepitant 150 mg \& aprepitant 165 mg reveals that the primary hypothesis will not be supported.

Eligibility criteria:
inclusion criteria: * generally healthy * female participants must be of non-childbearing potential * non-smoker or has not used nicotine or nicotine-containing products for at least 6 months exclusion criteria: * history of a clinically significant psychiatric disorder over the last 5 to 10 years * history of stroke, chronic seizures, or major neurological disorder * history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases * history of neoplastic disease * excessive consumption of alcohol (3 drinks/day) or caffeinated beverages (6 servings/day) * major surgery, donated or lost 1 unit of blood within 4 weeks * participated in another investigational study within 4 weeks * history of significant drug allergy or any clinically significant adverse experiences related to emend™, dexamethasone, or ondansetron * history of significant multiple and/or severe allergies * history of anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food * current drug/alcohol abuse, or history of such within 2 years * participation in a pet study or other study involving administration of a radioactive substance or ionizing radiation within the prior 12 months * extensive radiological examination within the prior 12 months * magnetizable metal prostheses or devices (magnetic resonance imaging (mri) hazard) * history of claustrophobia

Keywords: nk1-receptor occupancy
chronic kidney disease and myocardial injury after non cardiac surgery

Conditions: Myocardial Injury; Surgery; Chronic Kidney Diseases

Summary: investigators will conduct a retrospective chart review, examining the impact of chronic kidney disease on risk of myocardial injury after non cardiac surgery (mins). the objective of this study is to examine interactions between preoperative estimated glomerular filtration rate (egfr) and the association between preoperative n-terminal pro b-type natriuretic peptide (nt-probnp) and post operative cardiac events in patients undergoing major non cardiac surgery.

in recent years some authors have shown a correlation between increased post operative troponin and increased 30 day mortality in patients with kidney disease that mirrors the known correlation in those with normal renal function. in patients undergoing non cardiac surgery, walsh et al demonstrated a 4 to 6 fold increased risk of death associated with elevated post operative troponin in patients with reduced (\ 30ml/min) preoperative estimated glomerular filtration rate (egfr). a second, more recent study by liem et al, also found post operative troponin elevations were associated with higher morbidity and mortality risk in patients with chronic kidney disease undergoing non cardiac surgery. investigators aim to build upon the findings of these authors by examining the relationship between pre operative egfr, post operative troponin and risk of post operative cardiac events in patients undergoing non cardiac surgery at st paul's hospital. investigators will conduct a retrospective chart review of electronic records for all patients undergoing non cardiac, inpatient surgery at st paul's hospital from june 1, 2020 to december 31, 2021). investigators will include all patients for whom preoperative egfr values are available, and patients on chronic dialysis. patients are to be stratified by preoperative egfr and primary outcomes compared between patients with normal vs abnormal preoperative egfr. primary outcomes to be reviewed are myocardial injury after non cardiac surgery (mins) and troponin elevations.

Eligibility criteria:
inclusion criteria: * patients undergoing non cardiac surgery, at st paul's hospital, during the period spanning june 1 2020 to november 30 2020 * preoperative egfr data is available, or chronic dialysis status is known (these patients will not reliably have egfr measured, and it is not relevant) * inpatient surgeries (elective, urgent, and emergent) exclusion criteria: * patients undergoing cardiac surgery. * patients undergoing day surgery * patients for whom estimated glomerular filtration rate (egfr) results are not available

Keywords: mins chronic kidney disease
a randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy of nnc0114-0006 in subjects with active rheumatoid arthritis

Conditions: Inflammation; Rheumatoid Arthritis

Summary: this trial is conducted in europe. the aim of the trial is to evaluate the change in disease activity following intravenous (i.v.) administration of two doses of nnc0114-0006 compared to placebo in subjects with active rheumatoid arthritis (ra) on background methotrexate (mtx) therapy.


Eligibility criteria:
inclusion criteria: * a diagnosis of ra meeting the 2010 acr (american college of rheumatology) classification criteria, obtained at least 6 months prior to dosing with the trial product. (if the diagnosis was made prior to 2010, a diagnosis meeting the 1987 acr classification criteria is acceptable) * active ra characterised by das28-crp (disease activity score based on 28 joints and c-reactive protein) equal to or above 4.5 and at least five tender and five swollen joints (can be the same joints) of the 28 joint count * concomitant treatment with mtx above or equal to 15 mg/week for at least 4 months prior to screening, with stable dose of between or equal to 15 mg/week and 25 mg/week for at least 6 weeks prior to screening (mtx doses between 7.5 and 12.5 mg/week are allowed, if patient had intolerance to 15 mg/week) * biologic naïve subjects or subjects having been treated with biologics for ra (biologic experienced) provided they meet one of the following criteria: a. reason for discontinuation of biologic therapy was intolerance (e.g., unable to receive recommended doses or achieve adequate treatment duration because of drug related side effects), b. discontinued biologic therapy for other reasons than lack of efficacy (primary or secondary failure) or intolerance (e.g., drug holiday) exclusion criteria: * body mass index (bmi) below or equal to 18.0 or above or equal to 38.0 kg/m\^2 * subjects with rheumatic autoimmune disease other than ra, or significant systemic involvement secondary to ra (including but not limited to vasculitis, pulmonary fibrosis, or felty's syndrome). subjects with secondary sjögren's syndrome or stable hypothyroidism are eligible * any active or ongoing bacterial infections within 4 weeks prior to randomisation, unless treated and resolved with appropriate therapy (e.g., simple urinary tract infection) * any history of recurrent infections or conditions predisposing to chronic infections (e.g., bronchiectasis, chronic osteomyelitis) * history of severe systemic fungal infection within the past 12 months prior to screening unless treated and resolved with appropriate therapy
diet and lifestyle intervention study in postpartum women in china

Conditions: Puerperal Infection; Fever; Constipation; Hemorrhoids; Anal Fissure; Breast Disease; Oral Ulcers; Anemia

Summary: previous studies have shown "doing the month", a traditional practice for postpartum women in china and other asian countries, may be associated with higher prevalence of postpartum problems. the current multicenter randomized controlled trial (rct) aims to evaluate outcomes of diet and lifestyle interventions in chinese postpartum women.

the current multicenter rct will be conducted in three representative areas in china, shandong province, hubei province and guangdong province, which locate in northern, central and southern parts of china, respectively. women who attend routine pregnancy diagnosis in hospitals or maternal healthcare centers will be invited to take part in this study. at least 800 women who meet our eligibility criteria will be recruited and randomly assigned to the intervention group (n\>=400) and the control group (n\>=400). a three-dimension comprehensive intervention strategy, which incorporates intervention measures simultaneously to individual postpartum woman, their family members and community environment, will be utilized to maximize the effectiveness of intervention. regular visiting and follow-up will be done in both group; nutrition and health-related measurements will be assessed both before and after the intervention.

Eligibility criteria:
inclusion criteria: * healthy pregnant women * at their third trimester * had at least three routine examinations at these antenatal clinics exclusion criteria: * \ 40 years old
safety and efficacy of agn201781 in neuropathic pain

Conditions: Neuralgia

Summary: this study will explore the safety and efficacy of agn201781 in patients with postherpetic neuralgia or post-traumatic peripheral neuralgia


Eligibility criteria:
inclusion criteria: * diagnosis of postherpetic neuralgia or post-traumatic peripheral neuralgia * moderate or severe pain associated with postherpetic neuralgia or post-traumatic peripheral neuralgia exclusion criteria: * women of child-bearing potential * any other uncontrolled diseases
safety and efficacy study of ozurdex® compared to lucentis® in patients with branch retinal vein occlusion

Conditions: Retinal Vein Occlusion; Macular Edema

Summary: this study will evaluate the safety and efficacy of dexamethasone intravitreal implant (ozurdex®) compared to ranibizumab (lucentis®) in patients with branch retinal vein occlusion (brvo).


Eligibility criteria:
inclusion criteria: * diagnosis of branch retinal vein occlusion in at least one eye * visual acuity between 20/400 to 20/40 exclusion criteria: * active eye infection * ocular hypertension which is not controlled on monotherapy (one medication) * anticipated need for eye surgery during the study * cataract surgery in either eye within 3 months * eye surgery including laser of any type within 6 months * anti-vegf treatment in either eye (eg, lucentis®) within 3 months or systemic anti-vegf treatment (eg, avastin) within 6 months * use of ocular steroids within 3 months * use of steroids (except for inhaled or intranasal) within 1 month or anticipated use during the study
open label two-arm study to evaluate rilzabrutinib in igg4-related disease participants

Conditions: Immunoglobulin G4 Related Disease

Summary: this is a phase 2a, multi-center, open-label, two-arm study of approximately 25 patients with active igg4-related disease (igg4-rd). the two arms include (1) experimental: rilzabrutinib with glucocorticoids and (2) active comparator: glucocorticoids only.

4 weeks of screening, 12 weeks of main treatment, 12 weeks of cross-over (for gc-only group), 40 weeks of extension treatment and 4-week follow-up.

Eligibility criteria:
key inclusion criteria: * be male or female with age ≥18 years. * have a clinical diagnosis of igg4-rd. * be willing to taper off an equivalent prednisone dose of between 20-40 mg/day in 2 weeks. key exclusion criteria: * currently or within 6 months of screening taking rituximab, other b-cell depleting agents, or alkylating agents unless b cell concentrations have been demonstrated by flow cytometry to return to normal values (defined as 5 cells per cubic mm). * history of solid organ transplant * positive at screening for hiv, hepatitis b, hepatitis c, or tb * female patients who are pregnant or nursing. * note: other inclusion/exclusion criteria may apply.

Keywords: +igg4 glucocorticoid igg4-rd btk bruton's